Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Womens Health (Lond). 2023 Jan-Dec;19:17455057231170059. doi: 10.1177/17455057231170059.
Osteoporosis affects one in every five women over the age of 50 worldwide. With a rapidly ageing population, the prevalence of fragility fractures, considered a largely preventable consequence of osteoporosis, is expected to increase. Age is also a major risk for cardiovascular disease and mortality, thus highlighting the importance of cardiovascular profiling of osteoporosis interventions. Although calcium and vitamin D are essential for a healthy bone metabolism, excessive supplementation may be associated with increased risk. Conversely, early pre-clinical data have suggested a possible cardiovascular benefit from bisphosphonate therapy. This review evaluates the evidence behind the cardiovascular benefits and risks that may be associated with osteoporosis therapy.
骨质疏松症影响全球每五个 50 岁以上的女性中的一个。随着人口的迅速老龄化，脆性骨折的患病率预计将会增加，而脆性骨折被认为是骨质疏松症的一种主要可预防后果。年龄也是心血管疾病和死亡率的主要危险因素，因此强调了对骨质疏松症干预措施进行心血管评估的重要性。尽管钙和维生素 D 对于健康的骨骼代谢至关重要，但过量补充可能与风险增加有关。相反，早期临床前数据表明，双膦酸盐治疗可能具有心血管获益。本综述评估了与骨质疏松症治疗相关的心血管获益和风险的证据。
